Baker Bros. Advisors LP Erytech Pharma S.A. Transaction History

Baker Bros. Advisors LP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2018 Feb 13, 2019	SELL	$5.54 - $9.23 $6.02 Million - $10 Million	-1,085,969 Closed	0 $0
Q3 2018 Nov 14, 2018	SELL	$8.57 - $11.41 $17.1 Million - $22.8 Million	-2,000,000 Reduced 64.81%	1,085,969 $9.31 Million
Q2 2018 Aug 14, 2018	SELL	$11.17 - $21.41 $45,797 - $87,781	-4,100 Reduced 0.13%	3,085,969 $34.5 Million
Q4 2017 Feb 14, 2018	BUY	$17.93 - $30.3 $55.4 Million - $93.6 Million	3,090,069	3,090,069 $68 Million

Ticker ERYP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,018,600
Market Cap $16.8M
Description
ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. Its lead product candidate is eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of...

Get notified when there are updates to the investment portfolio of Baker Bros. Advisors LP, based on Form 13F filings with the SEC.

Stay updated on Baker Bros. Advisors LP with notifications on news.